Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Railway workers in Austria to strike Monday in pay standoff
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Railway workers in Austria to strike Monday in pay standoff
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Railway workers in Austria to strike Monday in pay standoff
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Railway workers in Austria to strike Monday in pay standoff
NASDAQ:PACB

Pacific Biosciences of California - PACB Stock Forecast, Price & News

$10.11
-0.24 (-2.32%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.95
$10.24
50-Day Range
$5.09
$11.20
52-Week Range
$3.85
$23.87
Volume
1.16 million shs
Average Volume
5.79 million shs
Market Capitalization
$2.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.40

Pacific Biosciences of California MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
82.0% Upside
$18.40 Price Target
Short Interest
Healthy
10.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Pacific Biosciences of California in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$600,505 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.36) to ($1.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

717th out of 1,044 stocks

Analytical Instruments Industry

21st out of 28 stocks

PACB stock logo

About Pacific Biosciences of California (NASDAQ:PACB) Stock

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Stock News Headlines

Pacific Biosciences of California (NASDAQ:PACB) Shares Down 4.5%
PacBio To Launch New Gene-Sequencing Systems
PacBio's (PACB) New Method for TR Profiling Now Available
Pacific Biosciences of California, Inc. (PACB)
PACB Pacific Biosciences of California, Inc.
PacBio Announces Second Quarter 2022 Financial Results
Pacific Biosciences: Lacks Forward Upside Capture
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Company Calendar

Last Earnings
11/02/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/21/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
728
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$18.40
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+82.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-181,220,000.00
Net Margins
-218.44%
Pretax Margin
-217.58%

Debt

Sales & Book Value

Annual Sales
$130.51 million
Book Value
$2.77 per share

Miscellaneous

Free Float
222,943,000
Market Cap
$2.29 billion
Optionable
Optionable
Beta
1.43

Social Links


Key Executives

  • Mr. Christian O. Henry M.B.A. (Age 54)
    Pres, CEO & Director
    Comp: $1.42M
  • Ms. Susan G. KimMs. Susan G. Kim (Age 46)
    Chief Financial Officer
    Comp: $671.49k
  • Mr. Mark Van Oene (Age 49)
    Chief Operating Officer
    Comp: $1.12M
  • Dr. Denis Zaccarin Ph.D. (Age 56)
    Sr. VP of Product Devel.
    Comp: $510.77k
  • Dr. Stephen Turner (Age 54)
    Co-Founder & CTO
  • Ms. Michele Farmer CPA (Age 42)
    VP & Chief Accounting Officer
  • Dr. Jonas Korlach Ph.D.
    Chief Scientific Officer
  • Trevin Rard
    Head of Investor Relations
  • Dr. Brett Atkins J.D.
    Ph.D., Gen. Counsel & Corp. Sec.
  • Ms. Natalie Welch
    Chief People Officer













PACB Stock - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PACB shares.
View PACB analyst ratings
or view top-rated stocks.

What is Pacific Biosciences of California's stock price forecast for 2023?

4 equities research analysts have issued 12 month price objectives for Pacific Biosciences of California's stock. Their PACB share price forecasts range from $8.00 to $40.00. On average, they expect the company's stock price to reach $18.40 in the next twelve months. This suggests a possible upside of 82.0% from the stock's current price.
View analysts price targets for PACB
or view top-rated stocks among Wall Street analysts.

How have PACB shares performed in 2022?

Pacific Biosciences of California's stock was trading at $20.46 at the start of the year. Since then, PACB stock has decreased by 50.6% and is now trading at $10.11.
View the best growth stocks for 2022 here
.

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our PACB earnings forecast
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01. The biotechnology company earned $34.89 million during the quarter, compared to analysts' expectations of $32.93 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 42.03% and a negative net margin of 218.44%. During the same quarter in the previous year, the firm posted ($0.14) EPS.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.70%), BlackRock Inc. (7.92%), Sumitomo Mitsui Trust Holdings Inc. (6.40%), Bellevue Group AG (2.41%), State Street Corp (2.23%) and Macquarie Group Ltd. (1.78%). Insiders that own company stock include Christian O Henry, Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Oene Mark Van, Peter Fromen, Susan G Kim, Susan K Barnes and William W Ericson.
View institutional ownership trends
.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $10.11.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $2.29 billion and generates $130.51 million in revenue each year. The biotechnology company earns $-181,220,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

The company employs 728 workers across the globe.

Does Pacific Biosciences of California have any subsidiaries?
The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More
How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.

This page (NASDAQ:PACB) was last updated on 11/27/2022 by MarketBeat.com Staff